Bruker (BRKR) Releases JPK NanoWizard 4 XP Bio-AFM System
Zacks Investment Research | Sep 02, 2019 09:19PM ET
Bruker Corporation (NASDAQ:BRKR) recently introduced the NanoWizard 4 XP extreme performance Bio-AFM system. The new system is the result of the integration of Bruker's exclusive PeakForce Tapping, which ensures both superior force control and unique AFM ease of use, and the pioneering QI mode for high-resolution nanomechanics on soft samples.
With the launch of this new system, the company has established a performance yardstick for atomic force microscopy in the field of life science research. This system will expand Bruker’s JPK BioAFM business’ portfolio under its NANO segment.
Bruker acquired JPK in July 2018 to incorporate the latter's expertise in live-cell imaging, cellular mechanics and biological stimulus-response classification into the former's global infrastructure.
More About the JPK NanoWizard 4 XP
Using JPK's groundbreaking role in fusing AFM with state-of-the-art optical techniques, the NanoWizard 4 XP system provides the most superior level of correlative microscopy and effortless integration with phase, DIC, confocal or spinning disc microscopies, single-molecule methods (FRET, FCS, TIRF, FLIM, FRAP), super-resolution techniques (STED, PALM/STORM, SIM), Raman, and multiphoton microscopy.
The PeakForce Tapping is an efficient way of attaining high-resolution AFM on a variety of biological samples. In addition to PeakForce Tapping and QI mode, the NanoWizard 4 XP builds on JPK's next-generation Vortis 2 high-speed, high-performance control electronics. The system also uses a path-breaking, new, workflow-based software, GUI, which comprises features like guidance, auto-setup and workspace organization to enhance productivity and deliver swift results.
Equipped with the widest array of accessories, the NanoWizard 4 XP is the most versatile Bio-AFM system in the market, as it offers remarkable flexibility for novel applications and experiments.
Recent Product Launches
Lately, Bruker has been focused on expanding its product portfolio.
In June 2019, the company launched the MALDI Biotyper sirius system for all previously FDA-approved and research-use-only (RUO) MALDI Biotyper (MBT) reference libraries, which are used for swift and cost-efficient microbial identification from cultures in microbiology.
In May, Bruker launched the timsTOF fleX mass spectrometer, which constitutes of a software-switchable MALDI source, adapted to the ESI timsTOF Pro platform.
Price Performance
Shares of the company have rallied 22.6% in the past year against the Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.